Skip to content

Visual Function Abnormalities in Strabismus and Amblyopia and Response to Therapy

Oculomotor Disorders: Experimental and Clinical Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04310241
Enrollment
150
Registered
2020-03-17
Start date
2020-02-21
Completion date
2027-03-12
Last updated
2026-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amblyopia, Strabismus

Brief summary

Amblyopia and strabismus are characterized by a reduction in visual acuity, contrast sensitivity, grating acuity, vernier acuity, reading difficulties and binocular visual function deficits. Treated patients have residual visual function deficits. The purpose of the current study is to quantify various visual functions in amblyopic and strabismic participants at baseline, during and at the completion of treatment.

Detailed description

To examine the response of therapy on visual functions in amblyopic and strabismic participants. The following visual functions will be measured prior to treatment. Eye movements, contrast sensitivity, grating acuity, visual acuity, vernier acuity, binocular visual functions, reading and visual scanning will be measured. The testing will comprise of one or more of the above paradigms depending on participant's cooperation and understanding as majority of the study participants will be children. The above measurements will be repeated during amblyopia therapy ( which comprises of glasses, patching and/or atropine eye drops) and at the completion of treatment. For participants with strabismus requiring strabismus surgery the measurements will be repeated after strabismus surgery.

Interventions

BEHAVIORALPatching therapy, Glasses

Patching, glasses and strabismus surgery are commonly employed measures in treatment of amblyopia and strabismus.

Sponsors

The Cleveland Clinic
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
6 Months to 90 Years
Healthy volunteers
No

Inclusion criteria

* History of amblyopia or presence of amblyogenic risk factors.

Exclusion criteria

* History of neurologic disorders

Design outcomes

Primary

MeasureTime frameDescription
Visual Functions0-3 years depending on duration of treatmentcontrast sensitivity
Visual functions0-3 years depending on duration of treatmentvernier acuity

Countries

United States

Contacts

CONTACTKimberly Baynes, MSN
baynesk@ccf.org216-444-2566
PRINCIPAL_INVESTIGATORFatema Ghasia, MD

The Cleveland Clinic

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 5, 2026